Roblon A/S reported increased revenue and earnings for the first half of 2024/25 Highlights  In H1 2024/25, consolidated revenue amounted to DKKm 113.0, against DKKm 110.6 in the year-earlier period. The Composite product group generated revenue growth, while the FOC product group’s revenue declined.   Operating profit before depreciation, amortisation and impairment (EBITDA) and before special items for H1 2024/25 was DKKm 26.2 (DKKm 15.1) and operating profit (EBIT) before special items was DKKm 19.0 (DKKm 6.8).  Consolidated revenue was realised at the lower end of the previously guided range, whereas earnings were realised at the upper end of the previously guided range for the first half. The improved earnings were due to a favourable product mix and realised productivity enhancements resulting from investments in production and ongoing...

Fiscal 2025 Fourth Quarter Highlights:Consolidated delivered sales of $571 millionUp 3% versus prior yearRetail segment delivered sales increased 8%Company-owned La-Z-Boy Furniture Galleries® network grew by a total of six stores; 203 company-owned store base now represents 55% of total networkWholesale segment delivered sales increased 2% GAAP operating margin of 5.2%; adjusted(1) operating margin of 9.4%, flat versus the year ago period GAAP diluted EPS of $0.36 and adjusted(1) diluted EPS of $0.92, both of which include a $0.10 impact from unfavorable foreign tax discrete items Delivered sales exceeded high end of guidance range and adjusted(1) operating margin at high end of guidance range Generated $62 million in operating cash flow for the quarter, up 17% versus prior yearFiscal 2025 Highlights:Consolidated delivered...

Management to Host Conference Call Tomorrow at 9:00 a.m. ET DURANGO, Colo., June 17, 2025 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, “RMC”, or “Rocky Mountain Chocolate”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, is reporting financial and operating results for its fiscal fourth quarter and fiscal year ended February 28, 2025. “Fiscal 2025 marked the beginning of a transformative era for Rocky Mountain Chocolate,” said Jeff Geygan, Interim CEO of the Company. “We initiated a comprehensive restructuring effort to revitalize the business—rebuilding our culture, restoring operational discipline, and modernizing core systems. We brought consumer packaging back in-house, implemented a new point-of-sale system...

Nanterre, 17 June 2025 VINCI Autoroutes and VINCI Airports traffic in May 2025 I-      Change in VINCI Autoroutes’ intercity networks traffic  May YTD at the end of May (5 months)  % change 2025/2024 % change 2025/2024VINCI Autoroutes -3.3% +1.2%Light vehicles -3.7% +1.3%Heavy vehicles -0.8% +0.6%The decline in VINCI Autoroutes’ May traffic is mainly due to calendar effects. In particular, light vehicle traffic was penalized by the positioning of the end of the Ascension weekend and the Pentecost weekend, in June this year instead of May in 2024. Since the beginning of the year, traffic levels have risen (+1.2%) for both light and heavy vehicles. II-      Change in VINCI Airports passenger traffic1  May YTD at the end of May(5 months)  % change 2025/2024 % change 2025/2024VINCI Airports +5.3% +6.7%Portugal...

Q1 2025 EBITDA at $103 million and net income of $38 million – equivalent to $1.04 eps Dividends exceed $900 million since Company’s NYSE listing in 2002 TEN awarded by Brazil’s Transpetro/Petrobras to build nine DP2 Shuttle Tankers on long-term employment with revenues of minimum $2 billion Total fleet contracted revenue backlog reaches approx. $3.7 billion Robust 21-vessel eco growth program underwayDr Irene Tsakos & Athens 04 delivered in Q2 ATHENS, Greece, June 17, 2025 (GLOBE NEWSWIRE) — TEN, Ltd (“TEN”) (NYSE: TEN) (or the “Company”) today reported results (unaudited) for the quarter ended March 31, 2025. Q1 2025 SUMMARY RESULTS TEN generated revenues of $197.1 million and operating income of $60.6 million. Net income reached $37.7 million and earnings per share of $1.04 in the first quarter of 2025. EBITDA for...

Q1 sales reached $13.5 million, representing a 0.6% increase year-over-year Gross profit margin rose to 51.1%, up from 43.3% in Q1 2024 Net loss significantly reduced to $0.2 million compared to $2.6 million in Q1 2024 Adjusted EBITDA turned positive at $1.6 million versus negative $0.8 million in Q1 2024 Cash position strengthened to $10.4 million, up from $8.8 million in Q1 2024MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (TSX-Venture: DTEA) (“DAVIDsTEA” or the “Company”), a leading North American tea merchant, today announced its financial results for the quarter ended May 3, 2025. “Our first-quarter performance demonstrates consistent execution of our omni-channel growth strategy and significant operational progress. Retail store sales rose 11.5% year-over-year, including 2.8% comparable store sales growth,...

EINDHOVEN, the Netherlands, June 17, 2025 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces its Q1 2025 business update and year-to-date highlights:Commercial traction: Following FDA market authorization, the Company met its Q1 objective for the limited initial phase of its US launch of the ARC-EX® System, hiring, training and deploying a field organization, establishing a sales and service process, building a roster of reference clinics, and selling ten systems. Technology advancement: The Company’s investigational ARC-IM® and ARC-BCI® platforms reached new milestones with the 4th and 5th successful BCI implants...

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational ProgressContinued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolio Varoglutamstat’s pre-clinical dataset showing synergistic effect in combination with an SGLT-2 inhibitor in different treatment regimens Novel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity for patent term extension Varoglutamstat meta-analysis data presented in oral presentation at ERA 2025 Preparations ongoing for Phase 2b of varoglutamstat in diabetic kidney disease (DKD) Management to host a conference call today at 3:00 pm CEST (9:00 am EDT)Halle (Saale) / Munich, Germany, June 17, 2025 – Vivoryon Therapeutics N.V....

                                             Les Ulis, June 17, 2025 at 7:00 a.m.ANNUAL RESULTS 2024-25 FOR THE LEXIBOOK GROUP: ANNUAL REVENUE AT €74.0M (+26.3%). EBIT AND NET INCOME UP, AT €8.1M AND €7.4M RESPECTIVELY, THANKS TO AN EXCEPTIONAL COMBINATION OF POSITIVE FACTORS. UNCERTAIN OUTLOOK FOR THE 2025-26 FISCAL YEAR DUE TO HIGH UNPREDICTABILITY REGARDING U.S. CUSTOMS DUTIES, FREIGHT COSTS, EXCHANGE RATES, AND CONSUMPTION.Annual Revenue: A record fiscal year after 5 consecutive years of growth. For the full fiscal year, which had already grown by 14.4% in 23-24, revenue rose again by 26.3% to €74.0M vs €58.6M a year earlier, notably thanks to the performance of licensed products.In a context of euro depreciation against the USD of around 1.0% over one year, and a very significant increase in freight costs, the Group’s margins...

FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025. Financial HighlightsThe Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment. The Company launched approximately 100 new products during the third-quarter of fiscal year 2025, and we are focusing on driving new revenues for those products. The Company’s third-quarter gross margin percentage was 39% (41% excluding a one-time...